Ozzy Osbourne cancels North American leg of No More Tours 2 due to health issues
The prolific frontman is heading to Europe for additional treatment.
Singer Ozzy Osbourne performs onstage at the 10th Annual MusiCares MAP Fund Concert to raise funds for MusiCares’ addiction recovery resources at Club Nokia on May 12, 2014 in Los Angeles, California. Image: Kevin Winter/WireImage
Ozzy Osbourne has announced that the North American leg of No More Tour 2 has been cancelled due to his ongoing battle with Parkinson’s disease.
The Prince of Darkness has decided to scrap the North American tour in its entirety for fear of having to cancel the tour halfway through due to his health issues. “I don’t want to start a tour and then cancel shows at the last minute, as it’s just not fair to the fans.” Osbourne said in a statement, “I’d rather they get a refund now and when I do the North American tour down the road, everyone who bought a ticket for these shows will be the first ones in line to purchase tickets at that time.”
The European leg of the tour is, however, unaffected by this cancellation. It begins on 23 October at the Utilita Arena in Newcastle, UK, and ends on 7 December, at the Hartwall Arena in Helsinki, Finland.
Osbourne recently disclosed that he was diagnosed with Parkinson’s disease following a fall that took place in his home. The North American leg of the tour had been postponed in January this year due to the accident, and slated to resume 27 May.
The tour is held in support of Osbourne’s latest album Ordinary Man which was released last Friday (14 February). It is the follow-up to 2010’s release Scream, and features a stellar cast of musicians – Elton John, Post Malone, and members from Rage Against The Machine, Red Hot Chili Peppers and Guns N’ Roses. This record was produced by Post Malone’s producer Andrew Watt, whom Ozzy met during a collaboration between the prolific rapper and himself on a track titled Take What You Want, for Post Malone’s album Hollywood’s Bleeding.
More information at ozzy.com.
Get the latest news, reviews and features to your inbox.Subscribe